We are live on ! Find out more
CGEM icon

Cullinan Therapeutics

146 hedge funds and large institutions have $799M invested in Cullinan Therapeutics in 2024 Q4 according to their latest regulatory filings, with 30 funds opening new positions, 54 increasing their positions, 36 reducing their positions, and 20 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more first-time investments, than exits

New positions opened: 30 | Existing positions closed: 20

50% more repeat investments, than reductions

Existing positions increased: 54 | Existing positions reduced: 36

29% more funds holding in top 10

Funds holding in top 10: 7 → 9 (+2)

7% more funds holding

Funds holding: 137 → 146 (+9)

4% less capital inflows, than outflows

Capital inflows: $118M | Capital outflows: $124M

1.66% less ownership

Funds ownership: 112.79% → 111.13% (-1.7%)

62% less call options, than puts

Call options by funds: $559K | Put options by funds: $1.45M

Holders
146
Holders Change
+9
Holders Change %
+6.57%
% of All Funds
1.91%
Holding in Top 10
9
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+28.57%
% of All Funds
0.12%
New
30
Increased
54
Reduced
36
Closed
20
Calls
$559​K
Puts
$1.45​M
Net Calls
-⁠$895​K
Net Calls Change
-⁠$9.9​M

CGEM Hedge Fund Activity: Q4 2024 in Review

146 of the 7,628 institutional investors tracked by Wall St. Rank reported a position in Cullinan Therapeutics (CGEM) for Q4 2024, worth a combined $799M — down 27% from $1.09B a quarter earlier.

Buyers outnumbered sellers: 30 funds opened new CGEM positions and 20 closed out — a net gain of 10 holders — while 54 added to existing stakes and 36 trimmed.

The largest buyer was Kynam Capital Management, opening a new position worth an estimated $18M. The largest seller was Paradigm Biocapital Advisors, exiting entirely with an estimated $38.9M sold.

  • 146 institutional investors held Cullinan Therapeutics (CGEM) as of Q4 2024, up from 137 in Q3 2024.
  • Funds reported $799M of Cullinan Therapeutics stock for Q4 2024, down 27% quarter-over-quarter.
  • 30 funds opened new Cullinan Therapeutics positions in Q4 2024 and 20 closed out, a net change of +10 holders.
  • The largest Cullinan Therapeutics buyer in Q4 2024 was Kynam Capital Management, an estimated $18M added.
  • The largest Cullinan Therapeutics seller in Q4 2024 was Paradigm Biocapital Advisors, an estimated $38.9M sold.

Based on aggregated 13F filings for Q4 2024.